GB8908921D0 - Recombinant avipox virus - Google Patents

Recombinant avipox virus

Info

Publication number
GB8908921D0
GB8908921D0 GB898908921A GB8908921A GB8908921D0 GB 8908921 D0 GB8908921 D0 GB 8908921D0 GB 898908921 A GB898908921 A GB 898908921A GB 8908921 A GB8908921 A GB 8908921A GB 8908921 D0 GB8908921 D0 GB 8908921D0
Authority
GB
United Kingdom
Prior art keywords
avipox virus
recombinant avipox
recombinant
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB898908921A
Other versions
GB2217718A (en
GB2217718B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US9071187A priority Critical
Priority to US11033587A priority
Priority to US18605488A priority
Priority to US23439088A priority
Priority to PCT/US1988/002816 priority patent/WO1989003429A1/en
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of GB8908921D0 publication Critical patent/GB8908921D0/en
Publication of GB2217718A publication Critical patent/GB2217718A/en
Application granted granted Critical
Publication of GB2217718B publication Critical patent/GB2217718B/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB8908921(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse Transcribing DNA Viruses
    • C12N2730/00011Reverse Transcribing DNA Viruses
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20111Lyssavirus, e.g. rabies virus
    • C12N2760/20122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
GB8908921A 1987-08-28 1988-08-24 Recombinant viruses,vaccines containing them and in vitro cell cultures thereof Expired - Lifetime GB2217718B (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US9071187A true 1987-08-28 1987-08-28
US11033587A true 1987-10-20 1987-10-20
US18605488A true 1988-04-25 1988-04-25
US23439088A true 1988-08-23 1988-08-23
PCT/US1988/002816 WO1989003429A1 (en) 1987-08-28 1988-08-24 Recombinant avipox virus

Publications (3)

Publication Number Publication Date
GB8908921D0 true GB8908921D0 (en) 1989-08-02
GB2217718A GB2217718A (en) 1989-11-01
GB2217718B GB2217718B (en) 1992-05-20

Family

ID=27492413

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8908921A Expired - Lifetime GB2217718B (en) 1987-08-28 1988-08-24 Recombinant viruses,vaccines containing them and in vitro cell cultures thereof

Country Status (17)

Country Link
JP (3) JP3348156B2 (en)
KR (1) KR970011149B1 (en)
AR (1) AR241939A1 (en)
AT (1) AT408549B (en)
AU (2) AU2427588A (en)
BE (1) BE1002134A5 (en)
CH (2) CH679934A5 (en)
DE (4) DE10399031I1 (en)
DK (1) DK175904B1 (en)
FR (1) FR2621487B1 (en)
GB (1) GB2217718B (en)
IL (1) IL87581D0 (en)
IT (1) IT1229484B (en)
LU (2) LU90951I2 (en)
NL (4) NL195051C (en)
NZ (1) NZ225970A (en)
WO (1) WO1989003429A1 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399031I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
US5286639A (en) * 1987-09-16 1994-02-15 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
CA2001001A1 (en) * 1988-10-21 1990-04-21 Matthew M. Binns Fowlpox virus promoter
DE3813093A1 (en) * 1988-04-19 1989-11-09 Immuno Ag A recombinant plasmid, method for producing a recombinant avipox virus, recombinant avipox virus, and its use
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
WO1989012684A1 (en) * 1988-06-24 1989-12-28 National Research Development Corporation Fowlpox virus non-essential regions
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
JP3955315B2 (en) * 1990-08-15 2007-08-08 ヴァイロジェネティクス コーポレイション Flavivirus recombinant poxvirus vaccine
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
FR2668064B1 (en) 1990-10-23 1994-12-16 Transgene Sa
US5503834A (en) * 1990-11-20 1996-04-02 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
IE71643B1 (en) * 1990-11-20 1997-02-26 Virogenetics Corp A recombinant poxviral vaccine for canine distemper
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5338679A (en) * 1991-01-08 1994-08-16 Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
AT247163T (en) * 1991-03-07 2003-08-15 Virogenetics Corp Genetically manufactured strain for vaccines
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
EP0575544A4 (en) * 1991-03-20 1997-05-21 Virogenetics Corp Malaria recombinant poxvirus vaccine
JP3504659B2 (en) * 1991-06-14 2004-03-08 ヴァイロジェネティクス コーポレイション Immunodeficiency virus recombinant poxvirus vaccine
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
AU670538B2 (en) * 1991-07-26 1996-07-25 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
ES2212795T3 (en) * 1991-08-26 2004-08-01 Baxter Healthcare S.A. Viruses of the viruela de las aves de recombinante corral.
US5443831A (en) * 1991-10-29 1995-08-22 University Of Delaware Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
DE69333728D1 (en) * 1992-01-13 2005-02-03 Virogenetics Corp Recombinant vaccinia virus as a vaccine against the marek virus
US6497882B1 (en) 1992-01-13 2002-12-24 Syntro Corporation Recombinant swinepox virus
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US6127163A (en) * 1992-01-13 2000-10-03 Syntro Corporation Recombinant swinepox virus
US6328975B1 (en) 1992-01-13 2001-12-11 Syntro Corporation Recombinant swinepox virus
US6251403B1 (en) 1992-01-13 2001-06-26 Syntro Corporation Recombinant swinepox virus
US6033904A (en) * 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
JPH08501452A (en) * 1992-09-21 1996-02-20 ビアジーン,インコーポレイティド Recombinant retrovirus vector for FELV and / or FIV
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
AU727278B2 (en) * 1993-02-26 2000-12-07 Syntro Corporation Recombinant fowlpox viruses and uses thereof II
AU6299594A (en) * 1993-02-26 1994-09-14 Nippon Zeon Co., Ltd. Recombinant fowlpox virus s-fpv-043 and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
AU731860B2 (en) 1996-07-25 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant pox virus for immunization against tumor-associated antigens
EP1515982A4 (en) 2001-05-09 2005-10-26 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
AU3910097A (en) * 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (en) 1997-12-01 1999-06-22 Lintec Corp Cover tape for carrying chip body and sealing structure
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1961819A3 (en) 2000-06-28 2008-11-12 Corixa Corporation Composition and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
AU2001256156B2 (en) 2000-02-23 2006-01-05 Smithkline Beecham Biologicals S.A. Novel compounds
DE60239317D1 (en) 2001-01-12 2011-04-14 Novartis Vaccines & Diagnostic Nucleic acid mucosal immunization
EP1370668B1 (en) * 2001-03-08 2006-02-22 Akzo Nobel N.V. Leporipox-based vector vaccines
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP2280074A3 (en) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
DK2224012T3 (en) 2001-12-17 2013-05-13 Corixa Corp Compositions and methods for therapy and diagnosis of inflammatory bowel diseases
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
AU2004204754B2 (en) 2003-01-06 2010-04-01 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CA2525825A1 (en) 2003-05-15 2005-01-27 Chiron Corporation Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
KR20070058631A (en) 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. Immunogenic composition
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
EP1979488A4 (en) 2006-01-09 2009-05-27 Univ California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
EP2253957B1 (en) 2006-03-14 2013-05-15 Oregon Health and Science University Methods for producing an immune response to tuberculosis.
CA2678404C (en) 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
AU2008314485B9 (en) 2007-10-15 2015-02-26 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CN105056229A (en) 2009-01-05 2015-11-18 埃皮托吉尼西斯股份有限公司 Adjuvant compositions and methods of use
US8664183B2 (en) 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
CN102713629B (en) 2009-11-20 2016-02-24 俄勒冈健康科学大学 For detecting the method for m tuberculosis infection
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
CN103608030A (en) 2011-06-21 2014-02-26 昂科发克特公司 Compositions and methods for therapy and diagnosis of cancer
EP2723378A4 (en) 2011-06-24 2015-01-28 Epitogenesis Inc Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
EP2890720B1 (en) 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
SG11201508297YA (en) 2013-04-17 2015-11-27 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
CA2938828A1 (en) 2014-02-06 2015-08-13 Genzyme Corporation Compositions and methods for treating and preventing macular degeneration
WO2016044707A1 (en) 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
WO2016183420A1 (en) 2015-05-13 2016-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for inducing an immune response using conserved element constructs
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK489481A (en) * 1980-11-10 1982-05-11 Searle & Co Plasmid vector and frmgangsmaade for the preparation thereof
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
JPH0795954B2 (en) * 1982-11-30 1995-10-18 アメリカ合衆国 Method for producing recombinant poxvirus for expression of foreign gene
FR2563434B1 (en) * 1984-04-25 1986-07-25 Transgene Sa Vaccination against rabies and process for its preparation
EP0190254A4 (en) * 1984-07-05 1987-03-09 Genex Corp Cloned gene and method for making and using the same.
DD235669A1 (en) * 1985-03-26 1986-05-14 Akad Wissenschaften Ddr Method for producing a blv-coded huel protein
DE3650289T2 (en) * 1985-03-29 1995-08-10 British Tech Group Spike protein of the virus of infectious bronchitis.
EP0213894A3 (en) * 1985-08-23 1987-10-21 Advanced Genetics Research Institute Defective viral particle vaccines and methods for their use
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
IL80073D0 (en) * 1985-09-25 1986-12-31 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome(aids)
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
AU8075787A (en) * 1986-09-22 1988-04-07 Australian National University, The Recombinant poxviruses
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
AU605567B2 (en) * 1987-03-11 1991-01-17 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
DE10399031I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
GB8724885D0 (en) * 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
FR2632863B2 (en) * 1987-10-29 1990-08-31 Transgene Sa Virus recombinant fowlpox vaccines and derivatives of these viruses
WO1989012684A1 (en) * 1988-06-24 1989-12-28 National Research Development Corporation Fowlpox virus non-essential regions
DE4090351T1 (en) * 1989-03-08 1997-07-24 Health Research Inc Recombinant smallpox virus host selection system
DE69132311D1 (en) * 1990-09-25 2000-08-17 Cantab Pharma Res Defective virus vaccine generated in a transcomplementing cell line

Also Published As

Publication number Publication date
AT408549B (en) 2001-12-27
IL87581D0 (en) 1989-01-31
GB2217718B (en) 1992-05-20
JP3348156B2 (en) 2002-11-20
DK175904B1 (en) 2005-06-06
NL300130I2 (en) 2005-11-01
BE1002134A5 (en) 1990-07-24
LU90951A9 (en)
DE10299049I1 (en) 2004-07-01
JPH02500879A (en) 1990-03-29
AR241939A1 (en) 1993-01-29
LU91039A9 (en)
IT8821772D0 (en) 1988-08-29
DE10399032I1 (en) 2004-01-29
NZ225970A (en) 1991-01-29
NL195051C (en) 2003-07-01
KR970011149B1 (en) 1997-07-07
FR2621487A1 (en) 1989-04-14
LU91039I2 (en) 2003-11-05
NL300138I2 (en) 2004-03-01
NL300138I1 (en) 2004-02-02
DK203689D0 (en) 1989-04-27
CH679934A5 (en) 1992-05-15
AU2427588A (en) 1989-05-02
DE3890874C2 (en) 2003-03-13
JP2002186494A (en) 2002-07-02
WO1989003429A1 (en) 1989-04-20
CH679933A5 (en) 1992-05-15
DE10399031I1 (en) 2004-01-29
FR2621487B1 (en) 1991-10-18
GB2217718A (en) 1989-11-01
AU1628895A (en) 1995-08-17
NL300139I1 (en) 2004-02-02
ATA900788A (en) 1995-05-15
NL8820679A (en) 1989-07-03
DE3890874C5 (en) 2005-10-20
NL300130I1 (en) 2003-09-01
DK203689A (en) 1989-06-27
IT1229484B (en) 1991-09-03
AU690210B2 (en) 1998-04-23
KR890701757A (en) 1989-12-21
JP2002348255A (en) 2002-12-04
JP3826055B2 (en) 2006-09-27
LU90951I2 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
ZA8906459B (en) Recombinant saccharomyces
GB8725529D0 (en) Polypeptides
IL86700D0 (en) Polypeptides
DE3856141D1 (en) Respiratorisches syncytiales virus, impstoffe
ZA9110129B (en) Recombinant antibodies.
DE10399031I1 (en) Recombinant viruses.
AU2618088A (en) Fowlpox virus promoters
GB8916806D0 (en) Modified proteins
DE10075024I1 (en) Peptides
JPS62221697A (en) Protein freeze protection
HK38293A (en) Hepatitis c virus
AU2634592A (en) Improved interferon therapy
GR871567B (en) Polypeptide derivatives
GB8607679D0 (en) Recombinant dna product
NZ249278A (en) Recombinant swinepox virus
GR3032940T3 (en) Recombinant retroviruses
JPS63215698A (en) Anticoagulant peptide
GR3022850T3 (en) Synthetic DNA derived recombinant HIV-1 antigens
PH23446A (en) Peptide preparations
EP0414689A4 (en) Pox virus vectors
GR860687B (en) Novel peptides
GB2212511B (en) Hepatitis c virus
DE3751664T2 (en) Recombinant vaccine
DE68927382D1 (en) RECOMBINANT Poultry Virus
ATA902590A (en) Recombinant small virus

Legal Events

Date Code Title Description
CTFF Supplementary protection certificate filed

Free format text: SPC/GB02/034: 20020904

CTFG Supplementary protection certificate granted

Spc suppl protection certif: SPC/GB02/034

Filing date: 20030501

Expiry date: 20130823

CTFF Supplementary protection certificate filed

Free format text: SPC/GB03/032: 20030904

Spc suppl protection certif: SPC/GB03/032

Filing date: 20030904

Free format text: SPC/GB03/031: 20030904

Spc suppl protection certif: SPC/GB03/031

Filing date: 20030904

CTFG Supplementary protection certificate granted

Free format text: SPC/GB03/031: 20040708, EXPIRES: 20130823

Spc suppl protection certif: SPC/GB03/031

Filing date: 20040708

Expiry date: 20130823

PE20 Patent expired after termination of 20 years

Expiry date: 20080823

CTFE Supplementary protection certificate entered into force

Spc suppl protection certif: SPC/GB02/034

Filing date: 20020904

Expiry date: 20080824

Extension date: 20130823

Spc suppl protection certif: SPC/GB03/031

Filing date: 20030904

Expiry date: 20080824

Extension date: 20130823

SPCE Supplementary protection certificate expired

Free format text: PRODUCT NAME: A COMBINATION OF RECOMBINANT CANARYPOX VIRUS-INFLUENZA A/EQUI-2/KENTUCKY/94 (RECOMBINANT CANARYPOX VIRUS THAT CONTAINS AND EXPRESSES ANTIGEN FROM INFLUENZA SUBTYPE A, EQUI2/KENTUCKY/94) AND RECOMBINANT CANARYPOX VIRUS-INFLUENZA A/EQUI-2/NEWMARKET/2/93 (RE; REGISTERED: UK EU/2/03/037/001 20030306; UK EU/2/03/037/002 20030306; UK EU/2/03/037/003 20030306; UK EU/2/03/037/004 20030306

Spc suppl protection certif: SPC/GB03/031

Filing date: 20030904

Expiry date: 20080824

Extension date: 20130823

Free format text: PRODUCT NAME: FEL V RECOMBINANT CANARYPOX VIRUS; REGISTERED: UK EU/2/02/031/001 20020308; UK EU/2/02/031/002 20020308

Spc suppl protection certif: SPC/GB02/034

Filing date: 20020904

Expiry date: 20080824

Extension date: 20130823